Compound ID | 79
Cefepime + enmetazobactam (Exblifep)
Synonym(s): AAI101 | OCID 5090
Class: Beta-lactam (cephalosporin, fourth generation) + beta-lactamase inhibitor (penicillanic acid sulfone)
| Spectrum of activity: | Gram-negative |
| Details of activity: | Active against Enterobacteriaceae; indicated for urinary tract infection, hospital and ventilation acquired bacterial pneumoniae, and complicated intraabdominal infection |
| Combined with other compounds: | Yes |
| Institute where first reported: | Allecra Therapeutics; Orchid Pharma |
| Year first mentioned: | 2015 |
| Highest developmental phase: | Approved by FDA in 2024 |
| Development status: | Approved |
| External links: | |
| Guide to Pharmacology: | cefepime |
| Main Source: | http://allecra.com/pipeline-2/ |
| Citations: |
|
AntibioticDB is supported by GARDP.
If you have feedback, experience problems, or are interested in a collaboration, please contact us.
The content of this site is intended for educational and scientific research purposes only and not as a source of medical advice or consultation.